Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Carcinoma, Renal Cell
Clinical trial register · China

Carcinoma, Renal Cell Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19212 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:17 UTC
19212
Studies in scope
all four open statuses
11805
Recruiting now
open to new participants
2029
Lead sponsors
across recruiting studies
Top sites
Beijing 8 Guangzhou 4 Chongqing 3 Zhengzhou 3 Wuhan 3
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing8 Guangzhou4 Chongqing3 Zhengzhou3 Wuhan3
All 18 locations
Target enrolment
to

Carcinoma, Renal Cell trials in China

10 of 19212 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Habitat Analysis of Tumor Thrombus for Vena Cava Wall Invasion in Renal Cell Carcinoma
NCT07901569Carcinoma, Renal Cell, Inferior Vena Cava Tumor Thrombus
Liu Zhuo
Observational
273
Beijing
2026-11-30
Not yet open
Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma
NCT07500831Carcinoma, Renal Cell, Metastatic Renal Cell Carcinoma, Advanced Renal Cell Carcinoma
Qilu Hospital of Shandong University
Not applicable
43
Jinan
2026-04
Recruiting
Pfizer
Phase 1/2
224
Beijing, Chongqing, Wuhan, Changsha, Nanjing, Jinan, Ningbo
2026-02-10
Recruiting
Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT
NCT07166445Carcinoma, Renal Cell, Diagnostic Imaging, Pathology, Deep Learning
Peking University First Hospital
Observational
1,000
Beijing
2024-09-01
Recruiting
Predicting Model Based on Evidence-based Pathological Diagnose Criteria for RCC Tumor Thrombus With IVC Wall Invasion
NCT05589207Carcinoma, Renal Cell, Tumor Thrombus, Neoplasm Invasiveness, Inferior Vena Cava Interruption
Peking University Third Hospital
Observational
232
Beijing
2023-01-01
Active, closed
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
Novartis Pharmaceuticals
Phase 1
126
Guangzhou, Beijing
2022-10-26
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan
2022-03-15
Recruiting
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
400
Shanghai
2019-10-01
Rows per page Showing 1–10 of 10
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 November 2026. https://priyalifescience.com/clinical-trials-china/condition/carcinoma-renal-cell

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,212 studies in total at the last sync on 10 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 10 of those studies listing the condition Carcinoma, Renal Cell.

How many Carcinoma, Renal Cell trials are recruiting in China?

4 of the 10 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:17 UTC sync. A further 2 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Carcinoma, Renal Cell), 10 studies
PhaseStudiesRecruitingShare
Observational4340%
Phase 33030%
Not applicable1010%
Phase 11010%
Phase 1/21110%

Most active sponsors

Lead sponsors with the most studies (Carcinoma, Renal Cell)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC30
Liu Zhuo10
Novartis Pharmaceuticals10
Peking University First Hospital11
Peking University Third Hospital11
Pfizer11
Qilu Hospital of Shandong University10
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.